Natsar Pharmaceuticals, Inc.

Funding and NIH signals

• SEC Form D raise Raised $4.22M (Form D filed May 8, 2026). SEC Form D 0002134002-26-000001 (May 8, 2026)
  Evidence (1 event)

  • May 8, 2026 · SEC Form D 0002134002-26-000001
    Name of Issuer: Natsar Pharmaceuticals, Inc.; CIK: 2134002; Address: Ellicott City, MD; Submission type: D; Filing date: 2026-05-08; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-23; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: Indefinite; Total Amount Sold: 4221000; Federal exemptions: 06b
• NIH award NIH awarded $615K (SBIR Phase II 5R44CA295155-02, continuation, notice Sep 17, 2026). NIH RePORTER 5R44CA295155-02 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 5R44CA295155-02
    Organization: NATSAR PHARMACEUTICALS, INC.; City/State: ELLICOTT CITY, MD; Project number: 5R44CA295155-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 615189; Administering IC: National Cancer Institute; Project title: Drug development of RK-33 for breast cancer treatment; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals